Photobiomodulation: What Red and Near-Infrared Light Can and Cannot Do
Light therapy has moved from fringe device to serious research question. The evidence is strongest exactly where the marketing is quietest.
By Rachel Vance · June 2, 2026 · 6 min read
Photobiomodulation describes the use of red and near-infrared wavelengths, roughly 600–1000 nm, to influence cellular function. The leading mechanism is absorption by cytochrome c oxidase in the mitochondrial electron transport chain, with downstream effects on ATP production and reactive oxygen signaling.
The clearest clinical evidence is in oral mucositis during cancer treatment, where intraoral laser therapy is recommended in several international guidelines. There is moderate support for musculoskeletal pain and wound healing, and early, inconclusive work in traumatic brain injury and neurodegenerative disease.
Dose is the whole argument
Photobiomodulation follows a biphasic dose response: too little does nothing, too much can inhibit. Wavelength, irradiance, total fluence, and treatment interval all matter, and consumer panels rarely specify them in a way that allows comparison with the studied parameters. A device that looks like the one in a trial may deliver a fraction of the dose.
The question is never whether light does something. It is whether this light, at this dose, does this thing.
Sources / Further reading
- Zadik et al., MASCC/ISOO clinical practice guidelines for oral mucositis, Support Care Cancer (2019)
- Hamblin, Mechanisms and applications of the anti-inflammatory effects of photobiomodulation, AIMS Biophys (2017)
- Huang et al., Biphasic dose response in low level light therapy, Dose Response (2009)
